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Abstract
Objective To perform a systematic review on commonly mea-
sured cerebral microdialysis (CMD) analytes and their associ-
ation to: (A) patient functional outcome, (B) neurophysiologic
measures, and (C) tissue outcome; after moderate/severe TBI.
The aim was to provide a foundation for next-generation
CMD studies and build on existing pragmatic expert guide-
lines for CMD.
Methods We searched MEDLINE, BIOSIS, EMBASE,
Global Health, Scopus, Cochrane Library (inception to
October 2016). Strength of evidence was adjudicated using
GRADE.
Results (A) Functional Outcome: 55 articles were included,
assessing outcome as mortality or Glasgow Outcome Scale
(GOS) at 3–6 months post-injury. Overall, there is GRADE
C evidence to support an association between CMD glucose,
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glutamate, glycerol, lactate, and LPR to patient outcome at 3–
6 months. (B) Neurophysiologic Measures: 59 articles were
included. Overall, there currently exists GRADE C level of
evidence supporting an association between elevated CMD
measured mean LPR, glutamate and glycerol with elevated
ICP and/or decreased CPP. In addition, there currently exists
GRADE C evidence to support an association between elevat-
ed mean lactate:pyruvate ratio (LPR) and low PbtO2.
Remaining CMD measures and physiologic outcomes
displayed GRADED or no evidence to support a relationship.
(C) Tissue Outcome: four studies were included. Given the
conflicting literature, the only conclusion that can be drawn
is acute/subacute phase elevation of CMD measured LPR is
associated with frontal lobe atrophy at 6 months.
Conclusions This systematic review replicates previously
documented relationships between CMD and various out-
come, which have driven clinical application of the technique.
Evidence assessments do not address the application of CMD
for exploring pathophysiology or titrating therapy in individ-
ual patients, and do not account for the modulatory effect of
therapy on outcome, triggered at different CMD thresholds in
individual centers. Our findings support clinical application of
CMD and refinement of existing guidelines.
Keywords Cerebral microdialysis . Systematic review .
Patient outcome . Functional outcome
Introduction
Cerebral microdialysis (CMD) has seen broad application
across neurocritical care [19, 24, 46]. By sampling brain pa-
renchymal extracellular fluid, CMD provides insights into
cellular metabolism and injury to guide clinical therapy, and
provide characterization of the host response (currently only
as a research tool) during pathologic states. To date, the largest
application of CMD is within the traumatic brain injury (TBI)
population [19, 46].
Commonly measured CMD analytes include: glucose, lac-
tate, pyruvate, (allowing calculation of the lactate:pyruvate
ratio (LPR)), glutamate, glycerol as well as the cations sodium
and potassium [41, 49, 50] (although the common presence of
these cations in the dialysis fluid makes their measurement
challenging). Other potential candidate biomarkers can be
measured from CMD samples, and an expanding panel in-
cludes immune cytokines and other biomolecules [35, 36].
However, these latter analytes are measured offline and do
not currently impact clinical practice.
Despite the wide application of CMD in TBI in neuro-
intensive care units (NICUs), the technique is still developing,
and the evidence base supporting its optimal use evolving.
Published expert consensus statements on the application of
multi-modal intracranial monitoring in general, and
microdialysis in particular, support the use of CMD as part
of a multi-modality panel [41, 49, 50]. These consensus state-
ments summarize key publications and provide a pragmatic
approach to the use of CMD based on collective current ex-
perience. Critically, much of this advice has been based on
outcome associations of monitored variables. However, there
has been no detailed systematic review of the literature using
standard evidence evaluation methodology.
The absence of such a review is unsurprising for several
reasons. First, the studies are heterogenous, and with a few
exceptions, involve small patient numbers. Second, interven-
tion thresholds based on microdialysis monitoring in these
studies vary substantially, and the consensus achieved in re-
cent publications has not been universally applied in the past.
Finally, despite the outcome associations that have been dem-
onstrated, any impact of a monitoring technique on outcome
will critically depend on the interventions that it triggers, and
these are both highly variable between centers, and generally
poorly described in the available literature. Consolidation of
the evidence base for optimal use of CMD may require a new
generation of studies, which couples the best estimate of crit-
ical monitoring thresholds identified by expert opinion and
physiological principles with standard approaches to data col-
lection and outcome assessment.
Critically, this new generation of studies will need a frame-
work for protocols that complies with quality metrics that
underpin evidence-based medicine. The development of such
a framework is dependent on a robust review of the available
literature, not just summarizing the evidence, but also identi-
fying whether and how a subsequent generation of studies can
be designed to provide further high-quality evidence to under-
pin clinical practice. We have therefore undertaken a rigorous
systematic review of the available literature addressing three
key questions:
– Do commonly measured CMD analytes display an asso-
ciation with patient functional outcome?
– Are these analytes associated with specific neurophysio-
logic changes seen during NICU care?
– Are these analytes associated with tissue outcome on im-
aging (such as acute ischemia/infarct, or atrophy long
term)?
Methods
A systematic review was conducted using the methodology
outlined in the Cochrane Handbook for Systematic Reviewers
[37]. Data were reported following the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses
(PRISMA) [59]. The review questions and search strategy
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were decided upon by the primary author (FAZ) and supervi-
sors (AH and DKM).
Search question, population, inclusion and exclusion
criteria
The questions posed for this systematic review were:
1. Do commonly measured CMD analytes have an associa-
tion with patient functional outcome in moderate and se-
vere TBI?
2. Do commonly measured CMD analytes have an associa-
tion with neuro-physiologic measures in moderate and
severe TBI?
3. Do commonly measured CMD analytes have an associa-
tion with tissue outcome/tissue fate in moderate and se-
vere TBI?
The CMD analytes that we included in the Bcommonly
measured^ category included: glucose, lactate, pyruvate,
LPR, potassium, sodium, glutamate, and glycerol. All studies
of five patients or more were included.
Functional outcome – outcome measures
and primary/secondary outcomes
The primary outcome measure was: documented association
between one of the CMDmeasures and patient outcome. Any
outcome score or mention of morbidity/mortality within the
studies was deemed acceptable. Secondary outcome measures
were: complications associated with CMD monitoring.
Neuro-physiologic measures – outcome measures
and primary/secondary outcomes
The physiologic parameters of interest were: ICP, CPP, PbtO2,
cerebral physiology and metabolism assessed using PET,
autoregulatory capacity (measured by any technique), and
CBF (assessed by any technique). All studies of five patients
or more were included. The primary outcome measure was:
documented association between one of the CMD measures
and one of the mentioned neuro-physiologic measures.
Secondary outcome measures were: complications associated
with CMD monitoring.
Tissue outcome – outcome measures and primary/secondary
outcomes
The tissue outcome of interest was ischemia/infarction during
acute/subacute hospital stay, primary lesion expansion during
acute/subacute stay, and cortical atrophy as assessed during
long-term follow-up imaging. Imaging studies deemed appro-
priate endpoints for association with CMD variables were
computed tomography (CT), magnetic resonance imaging
(MRI)/magnetic resonance spectroscopy (MRS), and a subset
of positron emission tomography (PET) studies (see below).
All studies of five patients or more were included. The prima-
ry outcome measure was: documented association between
one of the CMD measures and tissue outcome. Secondary
outcome measures were: complications associated with
CMD monitoring.
General inclusion/exclusion criteria
Inclusion criteria were: All studies including human subjects
with moderate or severe TBI (GCS of 12 or less), studies with
five or more patients, any age category, the use of CMD to
measure Bcommon^ analytes (glucose, lactate, pyruvate, LPR,
glutamate, glycerol) as well as potassium and sodium, and
documentation of either: (A) patient functional outcome in
relation to CMD measures, (B) documentation of neuro-
physiologic metrics in relation to CMD analytes, (C) the use
CMD to measure Bcommon^ analytes (glucose, lactate, pyru-
vate, LPR, glutamate, glycerol), and documentation of tissue
outcome in relation to CMD measures.
Exclusion criteria were: Non-English studies, animal stud-
ies and studies of less than five patients. Non-English studies
were excluded given the small number identified. For the
Btissue outcome^ portion of the review, positron emission
tomography (PET) tissue assessments based on 15O PET or
[18F] FDG PET were excluded due to the fact that these im-
aging modalities assess neurophysiologic parameters such as
metabolism and cerebral blood flow (CBF), not tissue out-
comes such as ischemia/infarction or cortical volume loss.
However, we sought to include PET studies that related
CMD variables to PET ligands that mapped survival of neu-
ronal populations at follow up (e.g., [11C]flumazenil PET and
GaBAergic neurons).
Search strategy
MEDLINE, BIOSIS, EMBASE, Global Health, SCOPUS,
and Cochrane Library from inception to October 2016 were
searched using individualized search strategies. The search
strategy for MEDLINE can be seen in Appendix A of the
supplementary material, with a similar search strategy utilized
for the other databases.
In addition, we surveyed relevant meeting proceedings for
the last 5 years for ongoing and unpublished work based on
CMD in moderate-to-severe TBI patients. The meeting pro-
ceedings of the professional societies that were searched can
be seen in Appendix A of the Supplementary materials.
Finally, reference lists of any review articles on CMDwere
searched for relevant studies on CMD.
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Study selection
Two reviewers undertook a two-step review of all articles
returned by our search strategies, separately for each review
question resulting in three separate systematic reviews.
First, reviewers independently (FZ and ET) screened titles
and abstracts of the returned articles to decide if they met
inclusion criteria. Second, full text of the chosen articles were
then assessed to confirm if they met the inclusion criteria and
that the primary outcome of patient functional outcome was
reported in the study (FZ and ET). Any discrepancies between
the two reviewers were resolved by a third reviewer if needed
(AH or DKM).
Data collection
Data were extracted from the selected articles and stored in an
electronic database. Data fields included: patient demo-
graphics, type of study, article location, number of patients,
CMD analyte measured, CMD measurement details (probe
tissue location, sampling frequency), outcome measure uti-
lized (outcome score, neuro-physiologic variable measured,
tissue outcome assessment technique etc.), association of
CMD measure to outcome (functional, neuro-physiologic, or
tissue), and complications to CMD.
Bias assessment
Two reviewers (FZ and RT) used the RTI item bank [102] to
assess bias in each study, with each component item graded as
Low-risk, High-risk, or Unclear. Discrepancies resolved by
discussion and a third party if needed (AH or DKM). This
bias assessment was repeated for each question of interest,
as there was some overlap in the articles between the review
on patient functional outcome and neuro-physiologic mea-
sures. Appendix B in the Supplementary Material provides a
table outlining details of risk assessment.
Quality of evidence assessment
Each reviewer (FZ and ET) used the Grading of
Recommendation Assessment Development and Education
(GRADE) criteria [30–33, 43, 85] to assess the level of evi-
dence for each CMD substrate and: (A) functional outcome,
(B) neuro-physiologic measure, (C) tissue outcome. Final
GRADE level was determined via consensus amongst the
group of authors.
The GRADE level of evidence is split into four levels: A,
B, C, and D. GRADE level A represents high evidence with
multiple high-quality studies having consistent results.
GRADE level B represents moderate evidence with one
high-quality study, or multiple low-quality studies. GRADE
level C evidence represents low evidence with one or more
studies with severe limitations. Finally, GRADE level D rep-
resents very low evidence based on either expert opinion or
few studies with severe limitations.
Statistical analysis
A meta-analysis was not performed in this study due to the
heterogeneity of data and study design within the articles
identified.
Results
Search strategy results
The PRISMA flow diagrams showing the search strategy is
available in Appendix A of the Supplementary materials.
Overall, 2739 articles were identified, with 2716 from the
database search and 23 from published meeting proceedings.
There were 1590 duplicates removed, leaving 1149 references
to review. Application of inclusion/exclusion criteria to the
title and abstract of these articles resulted in selection of 159
articles for full manuscript review across all three review
topics (Functional Outcome, (B) Neuro-physiologic
Measures, and Tissue Outcome). One additional reference
was added from the reference sections of review papers. A
second filter of these 160 references provided 55 that met
the final inclusion criteria for the Functional Outcome system-
atic review, 59 articles for inclusion the Neuro-physiologic
Measures systematic review, and four articles for the Tissue
Outcome systematic review.
We made substantial efforts to exclude duplicate patient
data across studies. However, given that many of the papers
came from centers of excellence for TBI research, some of the
patient data may be cross reported in multiple studies. This
would reduce the total overall number of unique patients. It
was impossible, based on the information provided, to tease
out all patients reported more than once.
Patient/study demographics
Functional outcome studies
Of the 55 articles included in the review [2, 3, 6, 8–10, 12–14,
16–18, 20, 21, 25, 27–29, 34, 38, 42, 44, 45, 47, 48, 51,
53–55, 60–62, 64–66, 68–71, 73–76, 80, 81, 86, 88, 91–93,
99, 103, 105, 107, 108], 33 were formal manuscript publica-
tions and 22 were meeting abstract publications. There were
26 prospective studies, with three randomized control trials
(RCT), 22 observational studies, and one single-arm study.
Thirteen studies were retrospective series. Finally, 16 studies
failed to clarify their study design [2, 3, 9, 14, 27, 28, 42, 45,
47, 60, 68, 76, 86, 103, 107, 108].
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All but three studies [29, 42, 103] described populations on
non-specified severe TBI patients, with no clear stratification
based on primary brain injury pattern on admission neuroim-
aging. Two studies focused only on patients post-
decompressive craniectomy (DC) [29, 103], with no clarifica-
tion as to the severity/pattern of primary injury. Finally, one
study focused only on patients with acute subdural hematomas
(aSDH) [42]. Furthermore, details of the intensive care unit
(ICU) treatments of these patients were not documented in
most studies. Many studies mentioned institutional ICU pro-
tocols and ICP/CPP protocols, without giving details of ther-
apies and individual variations in treatment. Furthermore, the
application of barbiturate coma, therapeutic hypothermia, and
DC were mentioned as potential therapies utilized, leading to
significant variation in treatments received by individual
patients.
Only three RCTs [2, 20, 65] and one prospective single arm
study [44] provided details of the planned intervention. Post-
TBI ICU care was mainly left unclear, stating BICP/CPP di-
rected protocols^, leaving room for significant procedural var-
iation between individual patients.
Across all studies there were 2786 patients with severe TBI
and assessment between common CMDmeasures and patient
functional outcome. Forty-three patients were post-DC and 19
had aSDH. The remaining 2724 patients were described as
severe-TBI patients without a detailed breakdown of injury
patterns alongside CMD measures/functional outcomes.
Table 1 displays a summary of the patient and study
demographics.
Neuro-physiologic measures studies
Of the 59 articles included in this systematic review [1, 3–5, 7,
10–13, 15, 17, 18, 21, 25, 26, 28, 34, 39, 40, 44, 47, 48, 51, 52,
56–58, 60–63, 68–72, 74–76, 78, 79, 81–84, 86, 87, 89, 91,
93–101, 105, 109], 30 were prospective observational studies,
four were prospective single-arm studies, one was a non-
randomized controlled study, and 12 were retrospective case
series. Twelve articles failed to provide enough information in
order to determine the exact type of study conducted [3, 15,
28, 47, 68, 76, 79, 82, 84, 86, 89, 109] and were classified as
Bunknown^.
Many studies in this category focused on patients with
severe TBI, without significant detail provided regarding the
pattern of injuries suffered by individual patients (focal versus
diffuse, etc). Furthermore, many studies failed to report CMD
measures based on subcategories of severe TBI, only
reporting mean values for the entire population studied. Two
studies focused only on severe TBI patients whom died, and
analyzed CMD measures during the herniation process [87,
96], and one study only included severe TBI patients on bar-
biturate therapy [26]. Descriptions of potential secondary in-
sults and therapies were very limited in the majority of studies.
Where such data were provided, details varied between stud-
ies, as did the therapies employed in each study.
Reference to ICP/CPP directed care/therapies was made in
many studies, but the description as to how this was achieved
was limited or absent. Many studies included significant var-
iations in intensive care unit (ICU)-based therapies, including
barbiturates [12, 18, 26] and therapeutic hypothermia [61].
The Lund concept for post-TBI ICU care was applied in some
patients [62]. These limitations in data unavailability are un-
surprising, since the aims and focus of the different studies
was heterogeneous, and in general data were provided to ad-
dress the specific (often pathophysiological) relationship that
was being explored. However, these variations in disease
course and physiology, coupled with variations in therapy
and incomplete descriptions of the details of therapy made it
impossible to undertake comprehensive exploration of the re-
lationships between CMD variables and physiology or
therapy.
A total of 2610 patients were studied across all included
articles. The mean age varied across all studies, ranging from
8 years to 58.2 years. Twenty-three studies failed to disclose
the age of the patients [3, 10, 12, 15, 17, 21, 28, 34, 47, 58, 68,
72, 74, 76, 83, 84, 86, 89, 91, 93, 94, 96, 109]. Only four
studies reported the inclusion of a small number of pediatric
patients (age under 16) [51, 56, 61], with only one study
clearly displaying the number of pediatric patients [75].
Overall, the total number of pediatric patients is quite small.
Some studies included moderate TBI patients with the severe
cohorts. It was impossible to separate the two groups. As such,
the compiled patient data, both moderate and severe TBI, were
included within this review. Study and patient characteristics
can be seen in Table 2.
Tissue outcome studies
Three of the four articles included in the tissue outcome sys-
tematic review [22, 23, 53, 89] were prospective observational
studies [22, 23, 89] and one was a retrospective case series
[53]. All studies focused on the severe TBI patient population
with no specific subcategory of interest declared.
A total of 52 patients were studied. The age of the patients
studied was mentioned only in one study [53], where it was
reported as a mean of 30.1 years (range, 18–58 years). No
specific details of patient comorbidities, acute phase treatment
of ICP/CPP, and complications related to critical illness were
report in any of the studies included in the review. Study and
patient demographics can be seen in Table 3.
CMD measurement technique
Details of the use of CMD monitoring were present in many
studies. The most commonly quoted sampling intervals
ranged from 30 min to hourly. Unfortunately, the use of
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pooled sample analysis was not always clear. Consequently,
despite hourly sampling, the data in most manuscripts did not
allow us to exclude the possibility that samples may have been
pooled over longer periods and analyzed for substrates over
these integrated time intervals.
The most commonly reported CMD measures included:
glucose, lactate, pyruvate, LPR, ± glutamate. Some studies
reported CMD measure of only one substrate, typically gluta-
mate or lactate.
A summary of the CMD measurement techniques for the
functional outcome, neuro-physiologic measure, and tissue
outcome studies can be seen in Appendix C of the
Supplementary materials. Furthermore, a study-by-study tab-
ulation of CMD measurement details can be seen in
Appendices E, F, and G of the Supplementary materials.
Measures of outcome
A summary of the various techniques employed in the mea-
surement of functional outcome, neuro-physiologic measures
and tissue outcome can be seen within Appendix D of the
supplementary materials. Furthermore, a study-by-study tab-
ulation of the outcome measure documented can be seen in
Appendices E, F, and G of the Supplementary materials.
Patient functional outcome - positive association studies
Glucose
Thirteen studies documented an association between CMD
measured glucose and mortality/Glasgow Outcome Scale
(GOS) at 3–6 months [6, 9, 29, 38, 48, 54, 64, 66, 73, 80,
105, 107, 108]. The documented association was that low
CMDglucose was associatedwith patient functional outcome.
The mean value for Blow^ CMD glucose varied across studies
(range, 0.46–1.39 mmol/l), with these values being signifi-
cantly lower than the Bgood^ outcome cohorts. Of note, one
study quoted a mean value of 13.8mmol/l in the poor outcome
group within a table, however we suspect this was a typo in
units (i.e., mmol/l instead of mg/l).
One study reported an association between high
lactate:glucose ratio (LGR) to outcome [54]. In addition, one
study reported an association between low brain:serum glu-
cose levels (<0.12) and poor patient outcome [48].
Glutamate
Fourteen studies documented an association between CMD-
measured glutamate levels and patient outcome as assessed by
mortality and GOS at 3–6 months [2, 12–14, 27, 38, 47, 55,
75, 76, 81, 86, 93, 105]. A threshold of glutamate greater than
20 µmol/l was reported in many of these studies to be associ-
ated with mortality and poor GOS at 3–6 months post-injury.Ta
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Glycerol
Fourteen studies reported an association between CMD mea-
sured glycerol and patient outcome, measured as mortality
and/or GOS at 3–6 months [8, 10, 17, 20, 28, 34, 42, 45, 51,
54, 69, 70, 93, 105]. There was a documented statistically
significant association between elevated mean CMD glycerol
levels and increased mortality/poor outcome at 3–6 months
[12–14, 27]. The reported ranges for Bhigh^ CMD glycerol
varied substantially across studies, with the Bpoor^ outcome
cohorts displayingmean levels ranging from 83 µmol/l to over
150 µmol/l.
Lactate/LPR
Twenty-five studies reported an association between CMD-
measured LPR and patient functional outcome, as assessed
by mortality and GOS at 3–6 months [8–10, 20, 21, 28, 34,
38, 42, 44, 45, 53, 55, 62, 65, 69, 71, 80, 86, 88, 92, 93, 99,
103, 105]. All studies documented a significant association
between elevated mean LPR (or baseline admission LPR)
and increased mortality/poor GOS at 3–6 months. The thresh-
old values reported for poor outcome varied significantly,
ranging from 25 up to and exceeding 80. The most commonly
quoted LPR thresholds for poor outcome ranged between 25
and 40.
Fourteen studies reported separate associations between the
mean CMD lactate concentration and increased mortality and/
or poor outcome at 3–6 months [2, 9, 18, 25, 38, 42, 54, 73,
80, 81, 93, 99, 107, 108]. Only one study made direct com-
ments about pyruvate levels and associated mortality/morbid-
ity. This study reported that sustained mean pyruvate levels
below 70 µmol/l, with LPR > 30, are associated with mortality
at 6 months [62].
Potassium
Only one study was found describing the association between
CMD potassium and patient outcome, as assessed via a di-
chotomized GOS at 3 months [74]. This study documented an
association between mean potassium levels less than
1.8 mmol/l and good outcome at 3 months (p < 0.0001).
The measurement of potassium levels in recovered
microdialysate can be challenging as the perfusion fluid often
contains potassium.
Neuro-physiologic measures – positive association studies
CMD association with ICP/CPP
Overall, there were 1684 patients described within studies
which found positive association between one or more com-
mon CMD measures and ICP and/or CPP.
The mean LPR was found to be associated with ICP/CPP
in 15 studies [1, 7, 10, 28, 34, 61, 62, 69, 79, 86, 87, 89, 93].
Seven studies displayed an association between elevated ICP
and an increase in LPR [7, 10, 69, 79, 87, 89, 93]. Four studies
displayed an association between low CPP and elevated LPR
[28, 62, 86, 91]. Finally, four studies described an association
between elevated ICP/low CPP and increased LPR [1, 34, 61,
94]. Various LPR thresholds were described for these relation-
ships, with and LPR of greater than 25 to 40 being the most
commonly quoted.
Elevated mean glutamate was found to be associated with
ICP/CPP in 11 studies [1, 7, 12, 26, 47, 56, 75, 82, 87, 93, 98].
Elevated mean glutamate was seen during episodes of in-
creased ICP in eight studies [7, 26, 47, 56, 75, 82, 87, 91],
and increased ICP/low CPP in three studies [1, 12, 98].
Glutamate thresholds for this association were seldom report-
ed, with only one study reporting levels greater than 20 µmol/l
as statistically associated with ICP/CPP [12].
Elevated mean glycerol was found to be associated with
ICP/CPP in 12 studies [1, 7, 10, 17, 34, 48, 61, 68, 69, 86–88].
Increased mean glycerol was seen during episodes of in-
creased ICP in seven studies [7, 10, 34, 68, 69, 87, 89], low
CPP in two studies [17, 86], and elevated ICP/low CPP in
three studies [1, 51, 61]. Like glutamate, glycerol thresholds
seen during these associations were not commonly described,
with only one study reporting a threshold of 100 µmol/l [7].
Some studies described relationships between common
CMD markers and ICP/CPP that were less robust. Mean
CMD lactate elevations, in isolation, were found to be associ-
ated with elevated ICP and/or low CPP in only four studies
[18, 25, 61, 78]. Low mean glucose was associated with ele-
vated ICP and/or low CPP in three studies [25, 48, 56].
Finally, high potassium levels were associated with ICP ele-
vations in one study [74].
CMD association with SjvO2
Three studies referred to some association between common
CMD measures and SjvO2, totaling 169 patients [15, 25, 82].
Elevated mean lactate was found to be associated with low
SjvO2 in three studies [15, 25, 82]. Increased mean glutamate
and glycerol were also found to be associated with low SjvO2
in two studies [15, 82].
CMD association with PbtO2
Eighteen studies made some reference to a positive associa-
tion between one or more common CMD measures and
PbtO2, totaling 746 patients [10, 17, 18, 21, 34, 47, 56, 58,
63, 72, 76, 82–84, 94–96, 101]. Location of the PbtO2 probe is
believed to have been near the CMD probe in all studies,
though this was not explicitly stated in the majority. Low
PbtO2 was found to be associated with elevated mean LPR
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in 11 studies [10, 15, 34, 48, 56, 63, 72, 94–96, 101], elevated
mean glycerol in three studies [17, 72, 82], elevated mean
glutamate in five studies [72, 76, 82, 83, 96], elevated mean
lactate alone in seven studies [18, 21, 58, 82, 95, 96, 101], low
mean glucose in three studies [48, 85, 101], and high mean
potassium in one study [96].
CMD association to autoregulation
An association between autoregulation measures and com-
mon CMD measures was reported in five studies, totaling
394 patients [4, 5, 93, 94, 105]. Pressure reactivity index
(PRx) monitoring was utilized in three studies, with an asso-
ciation between worsening autoregulation and elevated mean
LPR [93, 94, 105], glutamate [93], glycerol [93], and glucose
[105]. Two studies reported autoregulation measurement via
ICP computational waveform analysis, with an association
between poor autoregulation and elevated LPR [4, 5].
CMD associations with cerebral blood flow and metabolism
Ten studies reported an association between CMD analytes
and measures of cerebral blood flow using a variety of tech-
niques (PET, CTP, Xe CT, TCD (transcranial Doppler) or laser
Doppler flowmeter), totaling 372 patients [11, 39, 40, 51, 74,
76, 78, 99, 109].
Two studies reported a correlation between LPR and
15O PET measurements, with the following relationships
described: positive correlation between LPR and oxygen
extraction fraction (OEF) [39], and a negative correlation
between LPR and cerebral metabolic rate of oxygen con-
sumption (CRMO2) [97]. The ROI for these PET studies
was near the CMD catheter. A CTP-based assessment of
CBF was described in five studies. Two studies described
CTP based decreases in CBF in association with low
glucose/elevated LPR [11] and glycolytic lactate eleva-
tions [78]. Three studies utilized Xe CT, detailing an as-
sociation between elevated mean potassium [74], elevated
mean glutamate [108], and decreased mean glucose [99]
with reduced CBF. Transcranial Doppler ultrasonography
was applied in two studies. One described TCD based
decrease in CBF velocities associated with elevated mean
glutamate. The second study detailed laser Doppler flow-
meter assessment of CBF, with an association between
elevated glycerol and low CBF identified.
Two studies repor ted an assoc ia t ion between
fluorodeoxyglucose (FDG) PET and common CMD mea-
sures, with the following relationships: increased lactate/
pyruvate positively correlated to cerebral metabolic rate of
glucose consumption (CRMGLC) [40], and low glucose corre-
lated to increased FDG uptake [99].
Tissue outcome – positive association studies
Two studies included within the review were identified as
Bpositive^ studies, in that an association betweenCMDmeasures
and tissue fate were identified. Details can be seen in Table 3.
One of these studies was a meeting abstract describing the
use of MRS and MR diffusion tensor imaging (DTI) at an
undisclosed interval in the acute/subacute phase post-injury
[23]. The MRS analysis focused on N-acetyl aspartate
(NAA), choline (Cho), and creatinine (Cr) peaks, in addition
to apparent diffusion coefficient (ADC) onMRI imaging. The
goal was to identify possible areas of ischemia/infarction
using ADC thresholds and identify areas of neuronal loss on
MRS measures. The region of interest (ROI) for the MRS
voxel target was around the area of the CMD probe, which
was in an unspecified location (with radiologically normal (no
structural injury on CT) versus lesional tissue). The location of
the Bcontrol^ voxel was unclear in these patients. The study
demonstrated a negative correlation between CMD LPR and
MRS defined NAA (p = 0.037) and Cr peaks (p < 0.001). In
addition, CMD measured glucose was positively correlated
with the Cho peak (p = 0.007) and NAA/Cho ratio (p = 0.028).
The second Bpositive^ study focused on long-term assess-
ment of chronic frontal lobe atrophy at 6 months post-injury
[53]. This article utilized an MRI volumetric based assessment
of frontal lobe atrophy and attempted to determine an associa-
tion with acute/subacute CMDmeasures from Bhealthy tissue^.
It was found that the degree of LPR elevation and the duration
of abnormal LPR were positively associated with frontal lobe
atrophy at 6 months (p < 0.01). In addition, it was noted that the
percentage of time spend with LPR values greater than 40 di-
rectly correlated to frontal lobe atrophy at 6 months.
Nil association studies
Overall, for the majority of the studies identified documented
positive associations between one or more CMD analyte and
the various outcomes of interest. A minority of studies, and
thus the minority of the overall patient population documented
within the literature, reported a Bnil^ association between a
specific CMD analyte and outcome (i.e., functional, neuro-
physiologic, or tissue). A summary of the Bnil^ association
studies can be found within Appendix H of the
Supplementary materials. Furthermore, a study-by-study
breakdown of the Bnil^ association studies can be found in
Appendices E, F, and G of the Supplementary materials.
Complications of CMD monitoring
Functional outcome studies
Many studies failed to document complications/harms associ-
ated with CMD monitoring. Only four studies mentioned
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documentation of complications [8, 12, 65, 99]. Two studies
stated Bno complications^ [65, 99]. One study documented a
focal intra-cerebral hemorrhage (ICH) during insertion which
required surgical evacuation [4]. Finally, one study described
three instances of CMD catheter malfunction, requiring re-
insertion of a new catheter [12].
Neuro-physiologic measure studies
Only five studies reported complications related to CMD
monitoring [7, 12, 56, 98, 99]. Three studies reported Bno
complications^ related to CMD [7, 98, 99]. Two studies re-
ported CMD catheter malfunction in a total of five patients
[12, 56].
Tissue outcome studies
All studies identified failed to disclose any complications re-
lated to CMD monitoring.
Assessment of bias
The risk of bias was assessed via the RTI item bank [102],
with the results tabulated in Appendix B of the supple-
mentary material. Overall, all meeting abstracts included
within these systematic reviews were deemed very high
risk in almost all categories in the RTI bank. A short
descriptive reasoning for the bias assessments can also
be found in Appendix B.
Level of evidence
Functional outcome
As previously outlined, the level of evidence was assessed as
per GRADE criteria through consensus amongst the authors.
Given the overall high bias risk and shortcomings of all the
studies included within the systematic review, the level of
evidence ranges from low to very low in support of an asso-
ciation between commonCMDmeasures and patient outcome
as assessed by mortality and GOS at 3–6 months. A summary
can be seen in Table 4.
Neuro-physiologic measures
Overall level of evidence for the common CMDmeasures and
their relationship to physiologic measures were assessed via
the GRADE criteria. This assessment showed that most CMD
biomarkers displayed very low evidence in support of a rela-
tionship with specific physiologic measures. Given the limi-
tations listed above, we were limited in the strength of con-
clusions that we provide.
There currently exists GRADE C level of evidence
supporting an association between CMD measured LPR, glu-
tamate and glycerol with ICP and/or CPP. In addition, there
currently exists GRADE C evidence to support an association
between LPR and PbtO2. All remaining CMD measures
displayed either GRADE D evidence, or occasionally no ev-
idence, to support a relationship with physiologic measures. A
tabulated summary of the GRADE evidence can be seen in
Table 5.
Table 4 GRADE level of evidence for CMD measures and patient functional outcome
CMD measure Association with patient functional outcome GRADE level of evidence
Glucose Low mean glucose is associated with poor
outcome/mortality at 3–6 months post-injury
C (Low) – Large number of studies
with significant limitations
Glutamate High mean glutamate is associated with poor
outcome/mortality at 3–6 months post-injury
C (Low) – Large number of studies
with significant limitations
Glycerol High mean glycerol is associated with poor
outcome/mortality at 3–6 months post-injury
C (Low) – Large number of studies
with significant limitations
LPR Elevated mean LPR (>25 to 40) is associated with
poor outcome/mortality at 3–6 months post-injury
C (Low) – Large number of studies
with significant limitations
Lactate Elevated mean lactate is associated with poor
outcome/mortality at 3–6 months post-injury
C (Low) – Large number of studies
with significant limitations
Pyruvate Persistently low mean pyruvate levels, in the presence
of elevated LPR, is associated with üoor outcome
D (Very Low) – limited number of studies
evaluating pyruvate in isolation; significant
limitations identified within these studies
Potassium Mean potassium levels less than 1.8 mmol/l is associated
with a good GOS at 3 months post-injury
D (Very Low) – one study with limitations
Sodium There is no association between mean CMD sodium
levels and outcome
D (Very Low) – one study with limitations
CMD cerebral microdialysis, LPR lactate:pyruvate ratio, mmol millimolar, l liter, GOS Glasgow Outcome Scale
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Tissue outcome
Given the significant limitations in each study based on design
and bias risk assessment, it was difficult to assign a formal
GRADE level of evidence. Furthermore, there were studies
both in support and against any correlation between CMD
measures and tissue outcome. Thus, we are left with the fol-
lowing conclusions.
There exists GRADE D (very low) evidence to suggest an
association between CMD measured LPR greater than 40 in
the acute/subacute phase and frontal lobe atrophy at 6 months
post-injury.
There is unclear evidence to suggest a correlation between
CMD measures and MRS or ADC-based tissue outcome as-
sessment, with both low-quality evidence to support and re-
fute an association at this time.
Discussion
We believe that this three-stage systematic review in-
cludes the major available studies documenting the rela-
tionship between common CMD analytes and Patient
Functional Outcome (55 studies), Neurophysiologic
Measures (59 studies), and Tissue Outcome (four studies).
In broad terms, this systematic review replicates the prag-
matic summary of literature that underpinned the previous
consensus statements on CMD [41, 49, 50]. Our analysis
strengthens the evidence for many of these associations
by identifying a significantly larger number of studies
than were cited in recent consensus statements [49, 50].
Further, we document the level of evidence based on con-
ventional evaluation frameworks for evidence based med-
icine. This assessment found the following evidence:
1. Patient Functional Outcome - GRADE level C evidence
to support an association between CMD measured glu-
cose, glutamate, glycerol, lactate, LPR and patient func-
tional outcome as assessed by mortality and GOS at 3–
6months post-injury. These CMDmeasures have over ten
studies in support of this relationship, with the majority
documenting overwhelming statistical significance.
Furthermore, there exists GRADE D level of evidence
identified to support a relationship (positive or Bnil^) be-
tween CMD measured pyruvate, potassium, sodium, and
patient outcome. These CMD measures had much less
robust literature to support an association with outcome.
2. Neurophysiologic Measures – GRADE C evidence for a
relationship between elevated LPR and elevated ICP and/
or low CPP. We also judged that there was GRADE C
evidence supporting an association between elevated glu-
tamate and glycerol with elevated ICP and/or low CPP,
and between elevated mean LPR and low PbtO2. All re-
maining CMD measures displayed either GRADE D ev-
idence, or occasionally no evidence, to support a relation-
ship with physiologic measures.
3. Tissue Outcome – GRADE D of evidence to suggest an
association between LPR in the acute/subacute phase of
illness and frontal lobe atrophy at 6 months. The available
literature reports no consistent association between CMD
measures and MRS or ADC can be made at this time,
other than the literature is Bunclear .^
Table 5 GRADE level of evidence for association between CMD analytes and physiologic measures
Physiologic measure GRADE level of evidence CMD measure(s) Rationale
ICP/CPP C (low) LPR, glutamate, glycerol Several studies with large patient numbers
and statistically significant relations but
major study limitations in all
D (very low) Lactate (alone), pyruvate (alone),
glucose, potassium
Small number of studies with severe limitations
SjvO2 D (very low) Lactate (alone), glutamate, glycerol Very limited number of studies with
significant bias/limitation
PbtO2 C (low) LPR Several studies with severe limitations
D (very low) Glycerol, glutamate, lactate, p
otassium glucose
Very limited number of studies. All significantly
flawed. Publication bias high in this area.
Autoregulation
(PRx and ICP
waveform analysis)
D (very low) LPR, glutamate, glycerol Very limited number of studies. Bias high.
Publication bias very high.
Imaging No GRADE applied N/A This area of the literature was extremely scarce,
heterogeneous, suffering from publication bias,
design bias. Thus, we felt it inappropriate to assign
any GRADE level to this area at this time
ICP intracranial pressure, CPP cerebral perfusion pressure, CMD cerebral microdialysis, SjvO2 jugular venous oxygen saturation monitoring, PbtO2
brain tissue oxygen level monitoring, PRx pressure reactivity index monitoring, LPR lactate:pyruvate ratio
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However, we had also hoped that integration of the results
from these studies would allow us to draw more robust con-
clusions regarding the relationship of CMD variables and clin-
ical outcome or physiological metrics, with the large summed
sample size allowing greater methodological rigor and in-
creased statistical power. However, when compared to large
individual studies in the systematic review, the integration of
patients from all of the relevant studies did not provide more
robust statistical foundations for a specific CPP or ICP thresh-
old. Finally, we found a paucity of data in the area of tissue
outcome studies, which was surprising given that follow-up
imaging in this population should be common place, and ret-
rospective analysis of CMD measures and imaging based tis-
sue outcome should be possible. We were also surprised that
for the tissue outcome studies, the exclusive focus of the CMD
measures was lactate, pyruvate and LPR (i.e., markers of met-
abolic Bcrisis^). Glutamate and other excitatory amino acids,
and markers of tissue distress (glycerol) were not included in
most studies on tissue outcome assessment. Inclusion of these
markers may display a correlation to acute/subacute and
chronic tissue changes.
Limitations
Despite the interesting results generated by the systematic
review, we were unable to grade this evidence as being of a
high quality based on RTI criteria, because of the omission of
information which might have allowed us to grade the studies
at a higher level of evidence. The reasons for this discordance
are worth exploring, since its drivers will allow us to help
design data collection in a future generation of studies.
One critical set of limitations in most studies was the ab-
sence of clear statements that documented the absence of bias
in reporting, and hence resulted in categorizing these studies
as being at high risk of bias based on the criteria in the RTI
item bank [102]. There was some heterogeneity in reporting
and some studies may not suffered from the relevant biases,
but we were unable to exclude these based on the information
provided. One key issue is the basis for selection of the pa-
tients included in analysis in individual studies, since this im-
pacts substantially on the generalizability of the conclusions
we draw, and the population of patients in whom the results of
the study might apply.
A second key issue was the absence of documented
blinding of outcome assessors to the CMD results. While the
outcome assessors may not have been biased by knowledge of
the CMD results, the absence of clear documentation of such
blinding results in a downgrading of the quality of evidence in
studies based on RTI criteria. In addition, reported thresholds
for individual CMD measures and their association with out-
come were substantially varied. The definition of metabolic
abnormality in previous expert statements drew on knowledge
of pathophysiology and of study quality to make pragmatic
recommendations regarding metabolic thresholds. This more
comprehensive review of the literature shows substantial var-
iability, and without the filter of expert interpretation, does not
allow identification of consistent thresholds for most of the
measured substrates. Finally, complications (or the absence
of complications, and the method by which these were record-
ed) were seldom reported. This is an issue, an issue since the
overall number of patients was 2786 and only four patients
were reported as having issues secondary to CMDmonitoring,
leading to concerns about selective harms reporting. In order
to undertake a rigorous analysis of complications/harms asso-
ciated with CMD catheter placement, we also sought evidence
for these secondary endpoints in analysis of publications
which reported on physiological or imaging endpoints, but
provided no data on clinical outcomes. The available evidence
suggests that the placement of CMD probes may well be a
low-risk procedure [41, 49, 50], and is accurately reflected by
these numbers, but it is impossible to confirm or refute this
impression given the available information.
The third critical limitation stems from the focal nature of
CMD. Given that the CMD probe only samples a small vol-
ume, localized to the tip of the catheter, the results derived
from sample analysis provide only insights into focal regional
biochemistry. These focal biochemical profiles may not reflect
wider, or a more generalized average of, cerebral metabolism.
Consequently, inferring relationships between focal CMD
biochemistry and global outcomes of interest (functional out-
comes, neurophysiology, and/or tissue fate), has significant
limitations. However, given the limited ability to accurately
measure parenchymal biochemistry and metabolism, we are
left with the currently outlined literature base to assess the
association between these analytes of interest and various per-
tinent patient oriented outcomes.
A fourth critical set of limitations was the lack of charac-
terization of patients, especially in many smaller studies. This
both contributed to and complicated the limited analysis of
differences in CMD findings (and hence outcome associa-
tions) in different types of TBI (e.g., diffuse vs. extra-axial
hematomas vs. contusions). The location of catheter position
and the protocols for CMD sample pooling were not explicitly
stated in many studies, and hence make assessment of rela-
tionships between monitored variables and outcome relatively
crude. In addition, the exact volume of tissuemonitored by the
CMD probe is not clear, but it is unlikely to be representative
of entire regional, hemisphere or global chemistry in the set-
ting of TBI and is likely influenced by injury pattern and
treatment. The studies identified within this review fail to
delineate injury burden/pattern, and do not address the issue
of Bfocality^ of CMD. Thus, our overall conclusions are lim-
ited, hence the poor GRADE and RTI assessments for each
outcome of interest. The availability of details of ICU man-
agement would have provided important insights into the re-
lationships that were observed in some studies and not in
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others, since certain responses to CMD triggers might have
impacted outcome while others might not. Further, it is evi-
dent that the CMD biochemical pattern varies significantly
over time, during the course of disease evolution following
TBI. The timing and duration of these abnormal CMD pat-
terns are of importance. It is possible that either very early
abnormalities may have import because they dictate the sub-
sequent course of pathophysiology, or that persistent and late
emerging abnormalities in the setting of extreme physiologic
events (such as refractory ICP) are more related to clinical
outcome. However, the current literature identified within this
review is not amenable to such temporal profile analysis and
thus our comments on such are limited. Such refined analysis
of data with knowledge of key variables would substantially
add to the richness and reproducibility of any conclusions that
we could draw. Indeed, where such data are available, in both
small and large studies, they provide important insights into
the information provided by CMD [12, 20, 28, 63–65, 84, 93].
However, these data were not consistently available. Such
variations, if unbiased, could be seen to replicate the Bnoise^
seen in pragmatic trials and hence not affect the quality of
conclusions that are drawn from the data. However, our in-
ability to ensure that this did not result in bias, resulted in a
downgrading of the quality of the studies, and was reflected in
our overall RTI assessments and GRADE level of evidence
associated with each CMD analyte and the outcomes of
interest.
Additionally, given that we do not have robust data to
suggest/support Bnormal^ values of CMD measured
analytes, we cannot make firm comments on the how
the Bobserved^ biochemical changes reported within the
CMD studies should be interpreted in relation to Bnormal^
human brain values. We unfortunately are limited to
commenting on the relationship between CMD analytes
in those patients with poor clinical/physiologic progres-
sion versus those with good clinical/physiologic progres-
sion. It must be acknowledged that those patients with
Bgood^ clinical progression in no way represent Bnormal^
CMD analyte values, but merely the values recorded dur-
ing a desirable clinical or physiologic trajectory. These
recorded CMD analyte values are of course subject to
the treatments initiated within the ICU. Thus, in order to
better understand what we consider Bnormal^ or
Bacceptable^ levels of various CMD analytes in the set-
ting of TBI, large multi-center archived CMD data is re-
quired. Only through correlating the trend in these CMD
analytes to: injury pattern/burden, clinical course, other
multi-modal physiologic monitoring and the treatments
implemented, will we be able to more accurately comment
on what analyte values are Bnormal/acceptable^ in the
setting of TBI, and what values represent secondary dete-
rioration versus treatment effect. Finally, such data sets
would potentially allow for more definitive statements
regarding the association between common CMD analytes
and the outcomes we address in this review.
A fifth critical limitation was the substantial heterogeneity
in studies. The included papers varied by study design, pro-
spective versus retrospective nature, number of patients, pa-
tient inclusion criteria, ICU-based therapies offered/provided
to patients, blinding during outcome assessment, and primary
outcome of the studies. Many studies were written with the
purpose of describing primary outcomes other than the ones
we sought to review, with outcome information for the pur-
pose of this review provided as incidental information.
Selective outcome reporting with regards to individual CMD
measures and their association to all outcomes of interest was
present in most studies, since the focus in many of these stud-
ies was to elucidate pathophysiological relationships, rather
than seek outcome associations. Thus, the conclusions that
can be drawn from such data are limited. Consequently, most
CMD measures were deemed to have GRADE C (low), or D
(very low), evidence to support of an association. Given these
limitations and heterogeneity issues, a meta-analysis could not
be performed.
Finally, it is important to acknowledge that the evi-
dence summary and evaluation that we have undertaken
relate exclusively to use of CMD as a variable for specific
associations (functional outcome, other neurophysiologic
measures, and tissue outcome). The more common use of
CMD is as a tool for physiological monitoring, to identify
downstream consequences of insufficient oxygen and sub-
strate delivery or mitochondrial dysfunction, and trigger
changes in management. Indeed, though prognostic
thresholds were identified and published based on the data
in these papers, in many instances, the primary aim of the
relevant studies was to explore pathophysiology and as-
sess response to therapy. Microdialysis monitoring has
undoubtedly informed our understanding of the funda-
mental biology that underpins metabolic failure following
TBI, and provided a rational framework for therapy indi-
vidualization that can be addressed in interventional trials.
The current systematic review process does not address
these uses of microdialysis. Similarly, the strength of a
relationship between a measured CMD variable and func-
tional, or tissue, outcome could be modified by interven-
tions that were triggered by the CMD measurement. The
available data did not allow us to explore the modulatory
effect of treatment on the relationship between CMD var-
iables and the various outcomes of interest for this review.
Technical standardization of microdialysis technique
Cerebral microdialysis is a flexible technique, but this leads to
an additional complexity in amalgamating data across studies.
These issues can be divided into methodological issues, and
targeting of tissue at risk. The commonest microdialysis
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catheters used in clinical practice are the CMA 70 (20-kDa
molecular weight cut off (MWCO)) and CMA 71 (100 kDa
MWCO) (CMA Microdialysis AB, Sweden). For the meta-
bolic intermediaries discussed in this review, which are of
small molecular weight (~200 Da), the effect of catheter
MWCO has little impact on the efficiency of recovery of the
molecules of interest [38]. This is not true of CMD for protein
biomarkers, but a full discussion of the methodological issues,
including alternative perfusion fluids, is outside the scope of
this review [35]. The flow rate through the microdialysis cath-
eter also has an impact on the extraction efficiency from the
brain ECF, but in clinical applications is typically 0.3 μl/min,
although much higher flow rates have been used for samples
involving rapid sampling in specialized circumstances.
As a focal technique, CMD catheters sample a small region
of brain and the location of the tip of the catheter has an impact
on the resulting data. In TBI, several approaches have been
taken including two catheter studies comparing perilesional
and radiologically normal brain on CT, in the same patient
[94]. The results from CMD must therefore be interpreted in
an individualized fashion based on the position of the micro-
dialysis catheter tip in relation to specific lesions. However, in
general, for patients without a focal lesion the catheter is typ-
ically inserted into right frontal lobe i.e. non-dominant, non-
eloquent cortex, and for focal lesions such as a contusion or
subdural hematoma, the catheter should be placed in the brain
adjacent (~2 cm) to the focal lesion targeting brain which is ‘at
risk’ but not irretrievably damaged.
Future directions
There is a large body of literature supporting the association
between commonCMDmeasures with both patient functional
outcomes and neuro-physiologic measures. This data has pro-
vided a basis for pragmatic expert recommendations for use of
CMD as a clinical monitoring variable. We confirm these
relationships, but our formal assessment of the evidence base
suggests many improvements that could be incorporated into
the reporting of future studies. We believe that addressing
additional factors could provide more robust evidence relating
CMD variables to outcome.
First, it seems clear that CMD variables will explain only
part of the outcome variation in TBI. This predicates several
conclusions. It is likely that large patient numbers will be
needed to robustly identify key relationships between CMD
and outcome, both overall, and also in selective patho-
anatomical groups (e.g. diffuse vs. focal injury). A definitive
large multicenter study, focused on CMD, could address this
issue, and there is a hope that ongoing prospective studies,
including CENTER-TBI [52] and TRACK -TBI [106], may
be positioned to answer some of these questions. However,
CMD is not part of the core data collection in either of these
studies, and patients with CMDmonitoring will only represent
a minority of the ICU patients recruited. Consequently, it is
important that we find ways to make use of all of the data that
emerges in this area, including those from smaller studies. We
would therefore recommend a common data elements ap-
proach to reporting in all CMD studies, with specification of
catheter site, location in relation to lesions, type of injury (e.g.,
by Marshall Grade), CMD thresholds used as triggers in clin-
ical management (ideally as specified by expert consensus
statements, while recognizing that these may be different from
those used as associations for outcome), and clear documen-
tation of outcome.
Second, it would be useful if the other variables that are
known to affect outcome are characterized in publications
(with a minimum suggested inclusion of variables that form
part of the IMPACT CT model [67, 77, 90, 104]. This would
allow us to identify not just the prognostic impact of CMD
variable, but also define the supplementary explanatory power
that they provide in addition to other well established variables
such as GCS and age.
Third, all studies need to explicitly report data that allow
assessment of bias. Some of the larger and more rigorous
studies in this review explicitly recognized some of these lim-
itations [93], but many neglected to report on these. These
data would include the basis on which patients were selected
for inclusion, how the study population reflected the broader
population of patients in recruiting center, a statement as to
whether the outcome assessors were blinded to CMD data, the
basis for reporting only some of the CMD variables available,
and inclusion of negative results where these are available.
Fourth, to the association between CMD analytes and the
three outcome measures we explored needs to be assessed in
the context of multimodality monitoring data. Ongoing pro-
spective studies, including CENTER-TBI [52] and TRACK -
TBI [106], may be best positioned to answer some of these
questions. It is unlikely that a single monitoring technique in
isolation will prove sufficient to predict physiology and
patient/tissue fate. A combination of multi-modal monitoring
techniques will we better enable us to understand the extent of
injury and ongoing physiologic/metabolic changes, and argu-
ably stand a better chance of enabling more targeted therapy
improved patient outcomes. We would encourage funding
bodies tomandate such data collection, and also allow funding
provision for such data curation so that legacy research can be
of high quality.
Fifth, with regards to imaging-based tissue outcome asso-
ciations, given the likely availability of data from centers of
excellence using CMD in the acute phase, and the common
use of follow-up imaging in TBI patients, we believe that a
retrospective analysis could substantially refine the way we
think about and use CMD, and provide guidance for subse-
quent prospective studies that address the relationship be-
tween CMD variables and tissue fate. It is likely, however,
that the patient numbers with both acute CMD data and late
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imaging are likely to be a minority of the population recruited
to research studies, even in centers of excellence.
Consequently, a collaborative analysis of the data across cen-
ters is likely to be needed to deliver adequate statistical power.
Such an analysis will have to address clear pitfalls, including
the amalgamation of imaging data from multiple platforms,
better characterization of individual patients in each study to
allow for covariate adjustment in combined analysis, and in-
novative statistical approaches to account for late imaging at
variable intervals post-TBI to maximize the number of pa-
tients who can be included. We also need to reach consensus
on the CMD variables that would be included in such analy-
ses, but given the retrospective, hypotheses setting nature of
this exercise, a case can be made for attempting to include the
widest range of CMD variables.
Finally, it would be useful to consider what imaging mo-
dalities would provide the best assessment of tissue fate in
such analysis in prospective studies, and when such tissue fate
should be assessed following TBI. The choice of imaging
modality is difficult. CT is a poor metric of tissue fate in
TBI, but its common (near universal) availability could make
it attractive as a measure of global or regional atrophy.
However, if being undertaken solely for the purpose of such
a research analysis, conventional structural MRI has many
advantages, including lack of radiation burden, better paren-
chymal contrast, the ability to differentiate cortical and white
matter loss, and good protocols for combining data from dif-
ferent platforms (partly derived from the dementia imaging
literature), especially if control data are also available for in-
dividual centers. In fact, it would be possible to relate CMD
variables to age calibratedmetrics of neuronal loss. Indeed, for
the next generation of analyses, many of which will be retro-
spective, a simple T1 weighted image could provide an excel-
lent basic assessment. However, future studies need to take
account of the fact that tissue injury in TBI may not present
just as pan-necrosis, but also as selective neuronal loss, which
may be undetectable by conventional MRI. Detection of this
process may provide a more sensitive outcome measure of the
metabolic abnormalities detected by CMD on one hand, and a
more relevant substrate for functional outcome on the other.
Selective neuronal loss (SNL) can be detected by diffusion
tensor imaging, MRS or [11C] flumazenil PET. The first two
of these modalities, and DTI in particular, are rapidly gaining
currency as routine research imaging techniques, and show
promise for future studies in this context. Further to this, the
timing of imaging studies may be crucial in achieving maxi-
mal sensitivity for imaging to provide a downstreammarker of
CMD detected physiological stress. While imaging at 6
months is common, a case can be made for earlier imaging
assessment in studies that specifically relationships with acute
CMD in the first few days and weeks post TBI, since this
could avoid the confound provided by late tissue loss caused
by la ter, and more persis tent processes such as
neuroinflammation. However, we also need to allow time for
any imaging changes to evolve. The retrospective analysis that
was discussed earlier, and data from ongoing large prospective
studies, such as CENTER-TBI [52] and TRACK-TBI [106],
which incorporate serial imaging, could provide guidance on
this in the future, but a time interval of 2–3 months might
provide the best balance between allowing maturation of the
impact of acute physiology and minimizing the confound
cause by subacute events.
The more rigorous process of data collection and analysis
that we describe will allow use to base future inferences on
high-quality studies (even if involving smaller numbers of
patients), and better inform the identification of key physio-
logical thresholds related to patient functional outcome and
imaging based tissue outcomes. Further studies and analyses
need to evaluate the link between abnormal CMD monitoring
and other multi-modal monitoring parameters, and to
subacute/chronic tissue outcomes. Our goal was to outline
the literature, comprehensively, and be critical of the rigor
and evidence. It is true that the current CMD literature suffers
from limitations, leading to some potential uncertainty regard-
ing its clinical application. Not addressing these issues will
restrict the quality of inferences we draw from data.
Conclusions
There currently exists GRADE C evidence to support an as-
sociation between low CMD measured glucose and poor pa-
tient functional outcome at 3–6 months in severe TBI.
Similarly, there exists GRADE C evidence to support an as-
sociation between high CMD measured glutamate, glycerol,
lactate, LPR and poor patient functional outcome at 3–
6 months in severe TBI. Furthermore, there currently exists
GRADE C level of evidence supporting an association be-
tween CMD measured LPR, glutamate and glycerol with
ICP and/or CPP. In addition, there currently exists GRADE
C evidence to support an association between LPR and PbtO2.
All remaining CMD measures displayed either GRADE D
evidence, or occasionally no evidence, to support a relation-
ship with physiologic measures. Finally, there currently exists
GRADE D evidence to suggest a potential association be-
tween elevated CMD measured LPR and frontal lobe atrophy
at 6 months post-severe TBI.
All studies reviewed suffer from significant bias, primarily
attributable to the primary focus of the individual studies in-
cluded in this review, which was different from the aims that
we sought to explore. Our analysis does not address the use of
CMD for characterizing pathophysiology or titrating therapy,
and cannot account for any modulation of CMD-outcome
relationships by therapy. However they clearly define a role
for a new generation of studies analyzing the relationship be-
tween common CMD measures and other methods of multi-
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modal monitoring with patient functional outcome. These
need to include the technical specification recommended in
past expert guidelines and provide appropriate documentation
that allows exclusion of bias.
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Comments
Zeiler and co-workers provide an extensive review about cerebral micro-
dialysis and outcome in traumatic brain injury. In contrast to many other
papers, the authors also included meeting proceedings. I do not think that
this is a problem; much more, it is problematic that duplicates could not
exactly be eliminated. However, the authors have adequately discussed
this limitation and the other limitations of the paper. Most of these limi-
tations are methods immanent limitations of cerebral microdialysis and
have to be kept in mind whenever interpreting the results of this method in
neuro-intensive-care patients as well as in animal studies.
Marcus Reinges.
Giessen, Germany.
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